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Introduction {#s1}
============

Bisphenol A (BPA), a high-volume chemical and widely used synthetic plasticizer, has known estrogenic activity and is a recognized endocrine-disrupting chemical (EDC). Extensive studies over the past two decades have evaluated its potential effects in multiple organs and biological systems including its capacity for augmenting carcinogenesis ([@c7]; [@c17]; [@c45]; [@c46]). Although research consensus has not been reached on adverse outcomes from BPA doses relevant to human exposures, it is widely appreciated that the developmental period is particularly sensitive to BPA exposures that may lead to long-lasting effects over the life span.

The prostate gland is a hormone-dependent reproductive organ that possesses a high rate of disease with aging. Currently, prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer-related deaths in U.S. men ([@c50]). Whereas androgens are essential for prostate growth and function, substantial evidence indicates that estrogens play key roles in prostate homeostasis and disease ([@c32]). Importantly, inappropriate estrogen exposures during prostate development, in terms of timing, type and dose, can reprogram the gland, drive differentiation defects and predispose to an increased risk of prostate cancer ([@c39]; [@c40]). Work from our laboratory ([@c20]; [@c41]), recently confirmed in an independent study ([@c61]), determined that brief early-life exposure to low-dose BPA ($10–50\;\mu g/{kg}\,\text{BW}$), although not sufficient to induce prostate lesions on its own, increased susceptibility to estrogen-driven prostatic intraepithelial neoplasia (PIN) in adulthood. This is germane because relative estradiol levels rise in the aging male ([@c57]), estrogens can transform adult prostate epithelium ([@c1]; [@c22]), accelerate cancer progression ([@c6]; [@c47]; [@c51]) and estrogen activity is amplified in advanced disease ([@c31]). Thus we posit that BPA reprograms prostate cells early in life resulting in a cellular memory that augments adult hormonal sensitivity. The molecular underpinnings of reprogramed prostatic memory appear to lie in epigenetic modifications that have been identified in prostates exposed perinatally to low-dose BPA that poise the cells for amplified responses to later estrogenic exposures. These include hypo- or hypermethylation of DNA that directly modifies gene expression ([@c8]; [@c20]; [@c52]), alterations in histone methylation marks that directly change gene transcription or prime the gene for elevated response to transcriptional signals in later life ([@c60]), as well as changes in the expression of noncoding RNAs ([@c21]). These epigenetic modifications initiated by BPA are mediated, in part, by changes in the activity of DNA methyltransferases (DMNTs), methyl-CpG binding domain proteins (Mbd2/4) and histone methyltransferases (HMTs) ([@c52]; [@c60]). Recent work from our laboratory has further identified that human prostate stem and progenitor cells are direct targets of BPA exposures leading to epigenomic modifications and, due to their long-lived nature, increased carcinogenic susceptibility ([@c4]; [@c21]; [@c42]; [@c43]).

Despite inroads that have been made in identifying BPA's potential role in prostate carcinogenesis, significant knowledge gaps remain that have hindered full utilization of this work in risk assessment analysis ([@c7]). First, a dose--response study of the prostatic carcinogenic response to BPA has not been undertaken and is necessary across a range of exposures that include average human exposure levels and occupational risks. Another critical factor is accurate determination of internal free-BPA levels soon after exposure, irrespective of exposure route, to provide environmental applicability of the responses noted as well as knowledge of the precise BPA quantities to which animals and tissues are exposed. An essential element that remains unresolved is whether the precancerous PIN lesions found in prior studies that implicate BPA-driven carcinogenic susceptibility can in fact progress to prostate cancer. Finally, connection of epigenetic reprogramed genes to carcinogenesis and documentation of altered DNA methylation in a dose-responsive manner is necessary to determine the pathological relevance of these molecular modifications.

The present study sought to address these critical elements by a multi-pronged approach. We first undertook a large dose--response analysis of rat prostatic lesions at 7 mo of age as a function of early-life BPA exposures, both without and with a 2-fold increase in adult estradiol levels to promote carcinogenesis. Endpoint analysis included detailed histopathology, apoptosis/proliferation assessments and separate examination of the lateral, dorsal, ventral prostate lobes and periurethral prostatic ducts---all with known differential sensitivities to hormonal carcinogenesis. This is especially important because some past BPA evaluations have only examined the larger ventral lobe, which has no homology in the human prostate gland ([@c34]). Periurethral prostatic ducts are particularly susceptible to estrogen-driven cancers ([@c1]) and provide added value to the present dataset. Next, the progression of high-grade PIN lesions to microinvasion and prostate adenocarcinoma was evaluated by undertaking a properly powered study to 1 y of age. Internal dosimetry for all BPA doses in individual rat pups was addressed through development of low volume quantitative capacity for both free-BPA and BPA-glucuronide (BPA-G) using UHPLC-MS-MS. Finally, we extended our ongoing DNA methylation analysis of identified reprogramed genes ([@c8]) across a dose-range and found that permanent methylation changes were often most robust at the lowest BPA exposure levels. Together, these results firmly document that developmental exposures to low, environmentally relevant levels of BPA modify the prostatic DNA methylome in a dose-responsive manner and drive a significant increase in rat prostate cancer incidence that is lobe-specific and BPA dose-dependent.

Materials and Methods {#s2}
=====================

Animal Housing and Treatments {#s2.1}
-----------------------------

All animals were treated humanely and with regard for alleviation of suffering, using protocols approved by the Animal Use Committee at UIC.Timed pregnant Sprague-Dawley rats between 3 and 6 mo of age (Zivic-Miller Laboratories, Pittsburgh, PA) were shipped on gestation d 12 and housed under strict conditions as described ([@c41]). Rooms were maintained at $21{^\circ}C$ with 50% relative humidity and a 14-hr:10-hr light:dark schedule. All rats were housed in polysulfone solid-bottom cages with steel covers and double deionized water was supplied from glass bottles. Animals were fed *ad libitum* a soy-free, phytoestrogen-reduced diet (Zeigler Reduced Rodent Diet 2, Ziegler Bros, Inc., Gardners, PA). Pregnant dams were monitored and the day of birth was designated postnatal d 0 (PND 0). Litter size was culled to 10 pups on PND 0 by removing or adding female pups.

Newborn male pups were assigned to one of eight neonatal treatment groups with $22–32\,\text{pups}/\text{group}$ (see Figure S1A). To control for litter effects, male pups in each litter were randomly assigned to different treatment groups and tattooed for permanent identification. The 8 neonatal groups were *a*) tocopherol stripped corn oil vehicle as controls, *b*) high dose $\beta 17 - \text{estradiol}$ 3-benzoate ($\text{E}_{2}$), $2,500\;\mu g\,\text{E}_{2}/{kg}\,\text{BW}$, *c*) low-dose $\text{E}_{2}$, $0.1\;\mu g\,\text{E}_{2}/{kg}\,\text{BW}$, or 4--8) 0.1, 1.0, 10, 100, or $5,000\;\mu g\,\text{BPA}/{kg}\,\text{BW}$. The highest BPA dose is the current LOAEL for BPA established by the U.S. National Toxicology Program ([@c7]). All dosing was administered by subcutaneous (s.c.) depot injection in the nape of the neck on PND 1, 3 and 5 as previously described ([@c20]; [@c41]) thus allowing direct comparison of findings with our prior results. The timing of exposures coincides with the d 1--6 critical window characterized for the rodent prostate gland ([@c44]). On PND 3, tail vein blood was collected at 60 min postinjection from male rats in control and BPA dose groups ($n = 6–8/\text{group}$) using Microvette® CB300 capillary tubes (Sarstedt, Newton, NC). Sera was separated and frozen for internal dosimetry measurement of free BPA and BPA-G. All products used for collection and storage of samples were confirmed to be free of BPA contamination. The pups were weaned at PND 21 and housed two/cage.

At PND 90, approximately half of the rats from each neonatal treatment group were given implants of Silastic capsules (Dow Corning, Midland, MI; i.d. 1.02 mm, o.d. 2.16 mm) packed with estradiol (one 1-cm tube) and testosterone (two 2-cm tubes) ($T + E$) to drive prostate carcinogenesis as described ([@c20]). The T capsules maintain physiologic testosterone levels and are needed to maintain prostate homeostasis because estrogen treatment alone results in feedback inhibition of endogenous testosterone secretion with resultant prostatic involution. The estrogen capsules double the circulating estradiol levels, which is sufficient to promote prostate cancer in a rat model ([@c1]). Fresh tubes were replaced every 8 wk to ensure consistent steroid levels over time. At 7 mo of age (d 200), the animals were sacrificed by decapitation, blood collected and the prostatic-urethral complex quickly removed. This included the bilateral ventral, lateral and dorsal prostate lobes and the periurethral collecting ducts from each lobe that drain into the urethra (see Figure S1B). Using a dissection microscope, a single ventral, lateral and dorsal lobe from one side of each complex was removed, snap frozen, and stored in liquid nitrogen for molecular analysis. The remaining prostate lobes and full urethral complex were fixed *en masse* in methacarn (BBC Biochemical, Mt Vernon, WA) for 48--72 hr, rinsed and stored in 70% EtOH until histological processing. Serum was separated and frozen for hormone assays.

To examine potential progression of prostatic lesions to carcinoma, 60 control or $T + E$ treated rats were sacrificed at 1 y of age (D365) with a noted loss of $\sim 20\%$ of rats due to bladder outlet obstruction prior to 1 y. Five treatment groups ($n = 12/\text{group}$) included *a*) neonatal vehicle controls with empty implants at PND90, *b*) neonatal vehicle controls with $T + E$ implants at PND 90, *c*) neonatal low-dose $\text{E}_{2}\,\left( 0.1\;\mu g\,\text{E}_{2}/{kg}\,\text{BW} \right)$ with $T + E$ implants at PND90, *d*) neonatal high-dose $E_{2}\,\left( 2,500\;\mu g\,\text{E}_{2}/{kg}\,\text{BW} \right)$ with $T + E$ implants at PND90, and *e*) neonatal $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ with $T + E$ implants at PND 90. The $T + E$ implants were replaced every 8 wk. At 1 y, the rats were killed by decapitation, blood was collected, and the prostatic complex was dissected and processed for histopathologic diagnosis to assess carcinoma rates. This initial analysis of cancer rates was used for power analysis that determined that a doubling of the animal number would be required for proper calculation of carcinoma incidence. The entire study was then duplicated using identical vendors, diets, conditions, and rat strains for an additional 60 rats. When the histology data was decoded for treatment group, the results were similar to the original cohort and use of Bartlett's test for homogeneity of variance permitted the pooling of data between the two cohorts.

Histopathology {#s2.2}
--------------

The fixed prostatic tissues were dehydrated and paraffin embedded as described ([@c41]) with the ventral, lateral, and dorsal prostate lobes mounted along one plane surrounding the urethral region. Coronal sections of this complex permitted viewing of prostate structures *en masse* (see Figure S1). Three to four serial sections ($4\;\mu m$) were made at four levels of the block $150\;\mu m$ apart to permit pathologic analysis along the tissue depth and 12--16 sections were analyzed for each tissue. The sections were coded to prevent reader bias and stained with hematoxylin and eosin. Each prostatic region was read in a blinded fashion and scored for presence, severity and extent of lesions that include prostatic epithelial hyperplasia, inflammatory cell infiltration, and PIN. The PIN lesions were characterized by the presence of nuclear atypia (enlarged and elongated nuclei, hyperchromasia, prominent nucleoli) with or without aberrant cellular piling. Regions of cribiform pattern and aberrant cell piling without nuclear atypia were scored as atypical hyperplasia. PIN lesions were graded on a 0--3 scale with $0 = \text{no}\,\text{atypia}$, $1 = \text{low} - \text{grade}\,\text{PIN}$, $2 = \text{focal}\,\text{high} - \text{grade}\,\text{PIN}\,\left( \text{HGPIN} \right)$ and $3 = \text{extensive}\,\text{HGPIN}$. Other pathology included adenoma and squamous metaplasia and, at 1 y, basement membrane breakdown with local epithelial microinvasion and adenocarcinoma ([@c48]). In instances with uncertain diagnosis, a second pathology opinion was obtained and final classification reached by consensus. Once all histopathology diagnosis were completed, data were entered into a secured Excel database by a third party followed by decoding and data analysis. Incidences of the separate prostate lesions in each lobe were analyzed by chi-square and scores were analyzed by ANOVA followed by Fischer's exact test with significance accepted at $p < 0.05$.

Immunohistochemistry and *in Situ* Apoptosis Labeling {#s2.3}
-----------------------------------------------------

To assess epithelial proliferation rates, d-200 specimens ($n = 7 - 9/\text{group}$) were immunostained for $\text{Ki}–67$ using a polyclonal $\text{Ki}–67$ primary antibody (1:2,500, Novacastra, Newcastle, UK) with adjacent sections incubated in normal rabbit IgG ($0.5\;\mu m/{mL}$) as negative controls. To determine apoptosis rates by TUNEL staining, d-200 sections were reacted with an ApopTag Peroxidase In Situ Apoptosis Detection Kit according to manufacturer's instructions (Chemicon International, Temecula, CA). To calculate proliferation and apoptotic indices, multiple areas of each lobe were captured with a color digital AxioCam camera on an Axioskop microscope (Carl Zeiss, Inc., Thornwood, NY). Positive and negative $\text{Ki}–67$-stained or TUNEL-labeled epithelial cells were counted using Zeiss Image Version 3.0 (Carl Zeiss) with $\sim 1,000$ cells counted per slide. Data was analyzed by ANOVA and Bonferroni post-tests with $p < 0.05$ considered significant.

Bisphenol A Quantitation {#s2.4}
------------------------

Serum BPA was quantitated using a previously described HPLC-MS-MS methodology that permitted direct and simultaneous measures of free BPA and BPA-G in $25\;\mu l$ sera ([@c42]). As a participant in the NIEHS-coordinated round-robin BPA analysis that rigorously examined criteria required for accurate blood BPA measurements ([@c56]), quality control procedures were incorporated that included procedural blanks (LC-MS grade water; Burdick & Jackson, Honeywell, Muskegon, MI) and experimental blanks (charcoal-dextran stripped serum) analyzed with each experimental run. All equipment and supplies used in sera collection and storage and BPA measurements were confirmed free of BPA contamination. $\left\lbrack d_{6} \right\rbrack - \text{BPA}$ (Cambridge Isotope Laboratories, Andover, MA) $\left\lbrack rings -^{13}C_{12} \right\rbrack - \text{BPA} - G$, BPA (Sigma-Aldrich) and bisphenol A $\text{mono} - \beta - D - \text{glucuronide}$ (BPA-G; Midwest Research Institute, Kansas City, MO) were used as standards. Spiked BPA samples were analyzed for measurement accuracy.

Stock and working solutions of BPA and BPA-G were prepared in HPLC-grade methanol. Calibration standards were prepared by mixing $1\;\mu L$ of each working solution with $24\;\mu L$ blank rat serum. Sera from the $5,000\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ rats were initially run undiluted and repeated with 1:50 dilutions to ensure accuracy. All other samples were measured undiluted and deidentified for treatment groups. Each serum sample ($25\;\mu L$) or calibration standard was mixed with $100\;\mu L$ HPLC-grade acetonitrile containing the surrogate standards $5\,\text{ng}/{mL}\left\lbrack d_{6} \right\rbrack - \text{BPA}$ and $5\,\text{ng}/{mL}\left\lbrack {13C_{12}} \right\rbrack - \text{BPA} - G$, centrifuged at $13,000 \times g$ at 4°C for 15 min and the supernatant was removed and evaporated to dryness. The residue was reconstituted in $25\;\mu L$ of 50% aqueous methanol and a $5 - \mu L$ aliquot was injected onto the UHPLC-MS-MS system for analysis.

Chromatographic separations were carried out using a Shimadzu (Kyoto, Japan) LCMS-8050 triple quadrupole mass spectrometer equipped with a Shimadzu Nexera UHPLC system. Free BPA and BPA-G were separated on a Waters (Milford, MA) Acquity UPLC BEH ($2.1 \times 50\;{mm}$, $1.7 - \mu m$) $C_{18}$ column. A 1.5-min linear gradient was used from 10% to 100% acetonitrile in water followed by a hold at 100% for 0.3 min at a flow rate of $0.4\;{mL/min}$. Negative ion electrospray mass spectrometry with selected reaction monitoring (SRM) was used for measurement of each analyte using previously detailed SRM transitions ([@c42]). Data acquisition was carried out using Shimadzu Labsolution software for external calibration curve construction from standards run in each assay. The lower limits of detection (LOD) for free BPA and BPA-G in rat sera were 0.02 and $0.01\;{ng/mL}$, respectively, whereas the lower limits of quantitation (LLOQ) for free BPA and BPA-G were 0.2 and $0.1\;{ng/mL}$, respectively.

### Steroid radioimmunoassays (RIA). {#s2.4.1}

Frozen serum samples for testosterone (T) and $\text{estradiol} - 17\beta$ ($E_{2}$) analysis were shipped to the Ligand Assay and Analysis Core Laboratory (University of Virginia, Charlottesville, VA). Hormone levels were measured using murine RIA kits (TKTT2 for T and TKE21 for $E_{2}$; Siemens Medical Solutions Diagnostics). Sensitivity for T was $0.1\;{ng/mL}$ and the intra- and interassay coefficients of variance were 4.0% and 7.1%, respectively. For $E_{2}$, sensitivity was 10 pg/mL and the intra- and interassay coefficients of variance were 7.1% and 11.6%, respectively.

### Bisulfite PCR sequencing analysis. {#s2.4.2}

Genome-wide DNA methylation analysis using Roche-NimbleGen Rat ChIP 385 Promoter methylation arrays previously identified 20 genes with significant differentially methylated promoter regions in d-90 dorsal prostates of rats neonatally exposed to high-dose $\text{E}_{2}$ or $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ as compared to oil controls ([@c8]). Bisulfite sequencing validated the differential methylation patterns in 15 of the 20 genes and seven were confirmed to have gene expression status inversely correlated with promoter methylation status. In the present study, the CpG methylation status of five of these seven confirmed genes---*Sox2*, *Creb314, Paqr4, Pitx3* and *Tpd52*---was examined across the five neonatal BPA doses and high-dose $\text{E}_{2}$ exposure of d-200 dorsal prostates from rats without exogenous $T + E$ exposures to examine their persistence with aging and whether methylation status exhibited a dosage-dependent response.

Genomic DNA from d-200 dorsal prostates was extracted using DNeasy Blood & Tissue kit (Qiagen, Valencia, CA) with RNase A. Bisulfite sequencing of the gene promoters was conducted using 500-ng genomic DNA and EZ DNA Methylation kits (Zymo Research, Irvine, CA) as described ([@c8]). Following 40 cycles of PCR amplification, the amplicons were gel-purified and TA-cloned into pGEM T Easy Vector (Promega, Madison, WI). Plasmids from a single *E. coli* colony were directly amplified by TempliPhi DNA amplification kits (GE Healthcare, Buckinghamshire, UK) and sequenced (Macrogen USA, Rockville, MD). The methylation status at each CpG site was analyzed using BiQ Analyzer. Five day-200 dorsal prostate samples were used in each group. Promoter methylation at each CpG site was expressed as $\text{mean} \pm \text{SEM}$ from four to five samples/group with $4–6\,\text{clones}/\text{sample}$. The exception was Creb3/4 of which bisulfite sequencing analysis was performed on pooled samples ($n = 5$) with six clones/sample. For statistical analysis, area under the curve for promoter CpG methylation sites at each dose was calculated and significance determined by two-way ANOVA and Tukey test when compared to vehicle control prostates, with $p < 0.05$ considered significant.

Results {#s3}
=======

Quantitation of Free and Glucuronidated BPA in D-3 Rat Serum {#s3.1}
------------------------------------------------------------

An essential element for evaluating the biologic relevance of BPA administration across a dose--response range is internal dosimetry measurements that accurately quantitate circulating free-BPA and BPA-G levels shortly after exposure, irrespective of mode of BPA administration. Because BPA was administered on PND 1, 3, and 5, serum samples were collected from individual PND 3 rats via tail vein sampling 60 min after s.c. injection to determine the median free-BPA and BPA-G levels to which the developing tissues were exposed. As shown in [Table 1](#t1){ref-type="table"}, all vehicle-treated control rats had undetectable ($< \text{LOD}$) levels of free BPA and BPA-G, documenting a contamination-free system. Total BPA rose linearly in rat sera with increasing doses of BPA up to $5,000\;\mu g/{kg}\,\text{BW}$. At the two lowest BPA doses of 0.1 and $1.0\;\mu g\,\text{BPA}/{kg}\,\text{BW}$, free BPA was below the LOD and LLOQ, respectively, whereas BPA-G was $< \text{LLOQ}$ and $2.32\;\mu g\,\text{BPA}/{kg}\,\text{BW}$, respectively. Free BPA was first quantifiable in rats treated with $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$, appearing at $0.76\;{ng/mL}$, which is similar to our previous study ([@c41]) and within the range of fetal and newborn human exposures ([@c16]; [@c33]), thus implicating direct biologic relevance of this dosage. A nonlinear increase in free BPA was observed in the 100 and $5,000\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ treated rats, reaching $\sim 20$ and $1,492\;{ng/mL}$, respectively. Direct measurement of BPA-G revealed $33.55\;{ng/mL}$ in the $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ treated rats, which is markedly higher than our previous measures using indirect enzymatic treatment and extrapolation for BPA-G ([@c41]), emphasizing the improved accuracy and importance of direct BPA-G measurements. With this direct quantitative method, % free BPA in PND 3 rats was 2.2%, 7.7%, and 15% of total BPA for 10, 100, and $5,000\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ dosing levels, respectively, at 60 min postexposure.

###### 

Serum BPA levels in individual d 3 rats quantitated by UHPLC-MS-MS.

Table 1 lists treatments in the first column; the corresponding BPA concentrations (ng/mL) for free BPA, G-BPA, and total BPA are listed in the other columns.

  Treatment ($\mu g\,\text{BPA}/{kg}\,\text{BW}$)   BPA Concentration (ng/mL)                           
  ------------------------------------------------- --------------------------- ----------------------- -----------------------
  Vehicle                                           $< \text{LOD}$              $< \text{LOD}$          $< \text{LOD}$
  0.1                                               $< \text{LOD}$              $< \text{LLOQ}$         $< \text{LLOQ}$
  1                                                 $< \text{LLOQ}$             $2.318 \pm 0.873$       $2.318 \pm 0.873$
  10                                                $0.762 \pm 0.548$           $33.552 \pm 8.064$      $34.312 \pm 8.538$
  100                                               $20.32 \pm 1.22$            $244.01 \pm 36.98$      $264.33 \pm 36.15$
  5000                                              $1492.19 \pm 652.94$        $8354.60 \pm 1268.70$   $9846.85 \pm 1654.00$

Note: BPA in oil administered by subcutaneous injection. Serum collected at 1 h via tail vein. $\text{Mean} \pm \text{SEM}$; $n = 12–14\,\text{pups}\,\text{per}\,\text{group}$; G-BPA, glucuronidated BPA; LOD, limit of detection; LLOQ, lower limit of quantitation.

$\text{Total} = \text{Free}\,\text{BPA} + G - \text{BPA}$.

Neonatal BPA Exposures Increase Prostatic PIN and Hyperplasia at D 200 in a Lobe- and Dose-Specific Manner {#s3.2}
----------------------------------------------------------------------------------------------------------

Rats exposed to neonatal hormones without or with adult $T + E$ treatment were aged to d 200 and their prostates assessed in a blinded manner for the presence of PIN, atypical hyperplasia, epithelial hyperplasia and inflammatory cell infiltration. Neonatal exposure to increasing doses of BPA without adult hormone exposure produced minimal prostatic lesions at d 200 with no significant differences compared to aging controls (data not shown). The only group with significant pathologic alterations was neonatal high-dose $\text{E}_{2}$ as previously described by our laboratory ([@c20]; [@c37]).

In contrast, marked prostatic pathology was noted in a lobe-specific and dose-responsive manner in all neonatal $\text{E}_{2}$ and BPA treated rats when exposed to $T + E$ for 4 mo during adulthood ([Figure 1](#f1){ref-type="fig"}, [Table 2](#t2){ref-type="table"}; see also Table S1). It is important to note that the $T + E$ capsules produced identical serum testosterone levels and only 2-fold higher $\text{estradiol} - 17\beta$ levels as compared to control rats given empty capsules (see Figure S2), which is sufficient to initiate moderate prostate carcinogenesis with aging in this rat model ([@c1]). As expected, the lateral prostate lobe was most sensitive to adult hormone-induced carcinogenesis. PIN incidence (%) and severity score (scale 0--3) increased from 20% and 0.30, respectively, in the neonatal vehicle controls-empty adult capsule group to 67% and 1.46 in neonatal controls given $T + E$ during adulthood ([Table 2](#t2){ref-type="table"}). Importantly, PIN incidence and scores in the lateral lobe were further increased to near maximal values when exposed early in life to high-$\text{E}_{2}$ and all BPA doses plus adult $T + E$, with an incidence and score of 100% and 2.54, respectively, at the lowest dose of $0.1\&\mu g\,\text{BPA}/{kg}\,\text{BW}$ ([Figure 1](#f1){ref-type="fig"}, [Table 2](#t2){ref-type="table"}). It is noteworthy that serum free BPA and BPA-G were $< \text{LOD}$ and LLOQ, respectively, at 1 hr postexposure in this dosing group, documenting that lateral prostatic effects occur at exceedingly low BPA exposures. Lateral lobe epithelial hyperplasia was prevalent in all aged prostates including neonatal controls without additional adult hormone exposures (empty) ([Table 2](#t2){ref-type="table"}) and this was not further exacerbated with neonatal $\text{E}_{2}$ or BPA exposures or adult $T + E$. Of note, the lateral lobes contained marked inflammatory cell infiltration upon adult $T + E$ treatment that was significantly augmented by neonatal high-dose $\text{E}_{2}$ and BPA exposures ([Table 2](#t2){ref-type="table"}).

![Prostatic intraepithelial neoplasia (PIN) scores (0--3 scale), % proliferation ($\text{Ki}67 + \text{cells}$) and % apoptosis (TUNEL labeling) in the lateral, dorsal and ventral prostate lobes and periurethral prostate ducts at d 200. Rats were treated neonatally with vehicle, low-dose $\text{E}_{2}$, high-dose $\text{E}_{2}$ and increasing doses of BPA on d 1, 3, and 5 of life. All rats were given $T + E$ implants at d 90 to drive hormonal carcinogenesis. $n = 8–11/\text{treatment}\,\text{group}$. $* = p < 0.05$ and $** = p < 0.01$ vs, neonatal vehicle within each lobe.](EHP1050_f1){#f1}

###### 

Lateral prostate (T&E) pathology in d-200 rats.

Table 2 lists treatments in the first column; the corresponding score and incidence values for PIN, hyperplasia, and inflammation are listed in the other columns.

  ${\mu g}/{kg}\,{BW}$                   PIN           Hyperplasia   Inflammation                                    
  -------------------------------------- ------------- ------------- -------------- ------ ------------ ------------ ------
  $\text{Vehicle} + \text{Empty}$        0.3           20%           0%             0.90   40%          0.00         0%
  $\text{Vehicle} + T\,\text{E}$         1.46          67%           33%            1.10   60%          0.89         67%
  Low $\text{E}_{2}$                     1.18          62%           25%            0.38   25%          1.38         75%
  High $\text{E}_{2}$                    2.46^*a,c*^   91%           73%^*c*^       0.73   64%          2.00^*b*^    100%
  0.1 BPA                                2.54^*a,c*^   100%          70%            0.80   60%          1.70^*a*^    90%
  1.0 BPA                                2.27^*c*^     89%           56%            0.56   67%          1.33         89%
  10 BPA                                 2.54^*a,c*^   100%          67%            0.67   56%          2.22^*b*^    100%
  100 BPA                                2.18          75%           62%            0.62   38%          1.25         50%
  5K BPA                                 2.75^*b,c*^   90%           80%^*a,c*^     0.80   80%^*c*^     1.90^*a*^    100%
  (*a*) vs. $\text{Veh} + T\,\text{E}$   $p < 0.05$    NS            $p < 0.05$     NS     NS           $p < 0.05$   NS
  (*b*) vs. $\text{Veh} + T\, E$         $p < 0.01$                                                     $p < 0.01$    
  (*c*) vs. Low $\text{E}_{2}$           $p < 0.05$                  $p < 0.05$            $p < 0.05$                 

Note: Scores were analyzed by ANOVA with *post hoc* Dunnett multiple comparisons.

Incidence was analyzed by chi-square and Fischer's exact test.

*All PIN* includes tissues with 1, 2, or 3 PIN scores.

*HGPIN* includes only 2 and 3 PIN scores. $n = 8–11/\text{group}$; NS, nonsignificant.

Prostatic lesions in the dorsal and ventral lobes and periurethral prostatic ducts presented at reduced incidence and severity upon neonatal $\text{E}_{2}$/BPA plus adult hormone exposures when compared to the lateral prostate. This provided an opportunity to assess the dose-responsiveness of neonatal BPA exposures on altering carcinogenic susceptibility. PIN lesions in the neonatal vehicle-adult $T + E$ group were low in these three regions, not affected by neonatal low-dose $\text{E}_{2}$ and increased by high-dose $\text{E}_{2}$ exposure ([Figure 1](#f1){ref-type="fig"}; see also Table S1). In contrast to the lateral lobe, PIN scores exhibited an inverted U-shaped dose response to rising neonatal BPA doses. Although nonsignificant increases were noted at 1 and $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ as compared to neonatal vehicle controls, a significant increase in PIN scores was observed in dorsal and ventral lobes at $100\;\mu g\,\text{BPA}/{kg}\,\text{BW}$. Notably, this dropped at the high dose of $5,000\;\mu g\,\text{BPA}/\text{kgBW}$ to levels seen with lower-dose BPA. In the periurethral prostatic ducts, PIN scores increased at all BPA doses compared to neonatal vehicle controls with significance at 1, 10, 100, and $5,000\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ and peak values at the 10- and $100 - \mu g$ doses. The decrease PIN score noted at the highest BPA dose suggests that increased carcinogenic response in these regions may be limited to low-dose BPA exposures. Although dorsal lobe hyperplasia was not affected by neonatal $\text{E}_{2}$/BPA (see Table S1), the ventral lobe and periurethral prostatic ducts exhibited significant augmentation in hyperplastic incidence and severity in the high $\text{E}_{2}$ and all BPA doses as compared to adult $T + E$ only (see Table S1). Additionally, inflammation was low in these prostatic regions with only modest and nonsignificant increases from neonatal BPA exposures.

Neonatal BPA Augments Prostatic Epithelial Proliferation and Apoptosis {#s3.3}
----------------------------------------------------------------------

Perturbations in epithelial proliferation and apoptosis are accepted biomarkers of precancerous prostatic lesions when combined with histopathology ([@c48]). To assess the pathological significance of high-grade PIN lesions, tissues from neonatal $\text{E}_{2}$ and selected BPA dose-groups given adult $T + E$ through d 200 were histologically assessed for epithelial proliferation and apoptosis using Ki67 and TUNEL assays. Although not affected by neonatal low-dose $\text{E}_{2}$, the proliferative and apoptotic indices were markedly increased in all prostate regions with neonatal high-dose $\text{E}_{2}$ exposure plus adult $T + E$ ([Figure 1](#f1){ref-type="fig"}), matching the known capacity for carcinoma progression with combined hormonal exposures ([@c28]; [@c63]). Importantly, neonatal exposures to 10 or $100\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ increased proliferation in the lateral, dorsal and ventral prostate epithelium to levels observed with high-$\text{E}_{2}$ exposure. Although a marked response to high-$\text{E}_{2}$/adult $T + E$ was seen in the periurethral prostatic ducts, the effect of neonatal BPA was less pronounced with a proliferative increase only noted at $100\;\mu g\,\text{BPA}/{kg}\,\text{BW}$. Matching the proliferative changes, a significant increase in epithelial apoptosis was noted in all prostatic regions at $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ and a further augmentation was noted at the $100 - \mu g$ dose ([Figure 1](#f1){ref-type="fig"}). Together, this imbalance in proliferation/apoptosis rates indicates pre-carcinogenic activity and provides objective support for the pathologic relevance of the heightened PIN susceptibility upon neonatal BPA exposures.

Progression to Local Invasion and Adenocarcinoma upon Aging to 1 Y {#s3.4}
------------------------------------------------------------------

To directly determine whether the d-200 high-grade PIN lesions progressed to cancer, a cohort of control rats (neonatal vehicle without or with adult $T + E$) and rats neonatally exposed to low/high $\text{E}_{2}$ or $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ with adult $T + E$ were aged to 1 y for detailed histopathologic analysis. Although serum testosterone and estradiol were lower at d-365 vs. d-200 rats given empty capsules, the $T + E$ capsules maintained equivalent testosterone and a 2-fold elevation in circulating $\text{estradiol} - 17\beta$ in rats at 1 y (see Figure S2). Control rats without adult hormones showed no lesion progression whereas controls with $T + E$ exhibited limited cancerous progression with a 17% incidence of microinvasion, the earliest recognizable form of prostate cancer as evidenced by basement membrane breakdown with epithelial cells invading the stroma ([@c2]; [@c3]). However, there were no newly formed malignant acini/glands, used for grading adenocarcinoma ([@c48]), in any of the prostatic regions in the vehicle empty or $T + E$ control rats ([Figure 2](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}; see also Table S2). In contrast, a progressive increase in microinvasion and formation of focal well-differentiated adenocarcinoma glands (carcinoma -- glandular) were observed in prostates of rats treated neonatally with $\text{E}_{2}$ or BPA plus adult hormones. The response to low- and high-dose $\text{E}_{2}$ was dose-related in the lateral lobe with maximal incidence of microinvasion (58%; $p = 0.006$) and newly formed adenocarcinoma (carcinoma -- glandular incidence of 23%; $p = 0.032$) seen with neonatal high-dose $\text{E}_{2}$ ([Table 3](#t3){ref-type="table"}). Notably, neonatal $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ produced an equivalent incidence of microinvasive carcinoma (62%; $p = 0.004$) as high-dose $\text{E}_{2}$ in the lateral lobe, whereas the incidence of newly formed cancerous glands was somewhat lower (carcinoma: glandular incidence of 14%; $p = 0.079$) in the $10 - \mu g$ BPA-treated rats. Similar progression to microinvasive cancer without or with discreet, newly formed cancerous glands was found in the other prostatic regions for the low-dose BPA group, although this did not reach significance (see Table S2). Together, these findings demonstrate for the first time that neonatal exposure to low-dose BPA combines with rising adult estradiol levels to drive prostate cancer with aging.

![Prostatic histopathology lesions at d 365 in the lateral lobe (*A--G*) and periurethral prostate ducts (*H*) of rats treated neonatally with $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ and $T + E$ implants at d 90. Examples of HG-PIN and *in situ* carcinoma (*A*,*C*) and local microinvasion of epithelium into stroma (*B*,*D*, arrows) were observed in the majority of $\text{BPA}/T + E$ treated lateral prostates. Focal regions of well-differentiated adenocarcinoma (arrowheads in E, 10 $\times$ and F, 20 $\times$ of same region and *G* from a different lateral lobe) were seen in several lateral prostates as evidenced by irregular small glandular structures within stroma with abortive glandular lumens, back-to-back lumens and loss of basement membranes (arrowheads). Regions of adenocarcinoma were also noted in periurethral prostatic ducts (*H*, arrowheads). *A--D*, *F--H*, same magnification as *G* with $\text{bar} = 50\;\mu m$; $E\,\text{bar} = 100\;\mu m$.](EHP1050_f2){#f2}

###### 

Lateral prostate (T&E) pathology in aged (d 365) rats.

Table 3 lists treatments in the first column; the corresponding score and incidence values for PIN, inflammation, hyperplasia, and carcinoma-microinvasion, and only incidence values for carcinoma-microinvasion and carcinoma- glandular are listed in the other columns.

  $\mu g/\text{k}\text{g}\,\text{B}\text{W}$   PIN           Carcinoma-Microinvasion   Carcinoma- Glandular   Inflammation   Hyperplasia                                                                        
  -------------------------------------------- ------------- ------------------------- ---------------------- -------------- ------------- ------------ ------------ ------------- -------------- ------------- -------------
  Vehicle Empty                                0.12          1/17                      6%                     0/17           0%            0/17         0%           0.00          0%             0.76          47%
  Vehicle T&E                                  1.50^*a*^     15/18                     83%^*a*^               3/18           17%           0/18         0%           1.28^*a*^     78%^*a*^       0.50          39%
  Lo $\text{E}_{2}$ T&E                        2.00^*a*^     12/14                     86%^*a*^               6/14           43%^*a*^      1/14         7%           1.14^*a*^     71%^*a*^       0.86          57%
  Hi $\text{E}_{2}$ T&E                        2.50^*a,b*^   24/26                     92%^*a*^               15/26          58%^*a,b*^    6/26         23%^*a,b*^   1.77^*a*^     77%^*a*^       1.81^*a,b*^   88%^*a,b*^
  BPA 10 T&E                                   2.48^*a,b*^   20/21                     95%^*a*^               13/21          62%^*a,b*^    3/21         14%          1.43^*a*^     95%^*a*^       0.67          52%
  (*a*) vs. Veh empty                          $p < 0.001$   $p < 0.0001$                                     $p < 0.01$                   $p < 0.01$                $p < 0.001$   $p < 0.0001$   $p < 0.001$   $p < 0.001$
  (*b*) vs. Veh T&E                            $p < 0.01$    NS                                               $p < 0.01$                   $p < 0.05$                NS            NS             $p < 0.001$   $p < 0.01$

Note: Scores were analyzed by ANOVA with *post hoc* Dunnett multiple comparison.

Incidence was analyzed by chi-square and Fischer's exact Test. $n = 14–21/\text{group}$. NS, nonsignificant.

DNA Methylome reprograming across BPA Doses at D 200 {#s3.5}
----------------------------------------------------

We recently identified multiple genes in d-90 rat dorsal prostates whose promoters bore reprogramed DNA methylation patterns as a result of neonatal $\text{E}_{2}$ and BPA exposures, leading to altered gene transcription ([@c8]). In the present study, five of these genes were selected for a dose--response analysis of DNA methylation status using bisulfite PCR sequencing in d-200 dorsal prostates of rats without adult $T + E$ treatment. The five genes (*Creb3l4*, *Tpd52*, *Pitx3*, *Paqr4*, and *Sox2*) were selected because they showed the greatest changes in promoter methylation in PND90 dorsal prostates as a function of neonatal $\text{E}_{2}$/BPA exposures as compared to vehicle-treated controls. Although the lateral lobes exhibited the highest PIN and carcinoma rates upon $T + E$ treatment, the dorsal lobes were selected given that a dose--response PIN phenotype incidence was observed thus pathologically validating other dose--response measures. Importantly, the dorsal lobe exhibited minimal inflammatory cells with hormone treatments whereas lateral prostates had a high incidence of inflammatory cell infiltration thus precluding a clean separation of prostatic cells from immune cells in lateral lobes. As shown in [Figure 3](#f3){ref-type="fig"}, *Creb314, Tpd52, Pitx3, Paqr4*, and *Sox2* were hypomethylated at promoter CpG sites by neonatal high-dose $\text{E}_{2}$ and BPA in a dose-dependent manner when compared to vehicle controls. Three dose-dependent patterns emerged. For three genes---*Creb314, Tpd52* and *Pitx*3---significant hypomethylation was observed at the lower BPA doses of 0.1, 1.0, and/or $10\,\text{BPA}\,\mu g/{kg}\,\text{BW}$, with a return towards vehicle control methylation levels at the higher BPA exposures. Of note, the hypomethylation changes in *Creb314* and *Tpd52* induced by neonatal 0.1 or $1.0\,\text{BPA}\,\mu g/{kg}\,\text{BW}$, respectively, were greater than that observed with high-dose $\text{E}_{2}$. A second methylation pattern was noted in *Paqr4* in which high-dose $\text{E}_{2}$ and all BPA doses significantly reduced promoter gene methylation to the same extent as compared to the vehicle control group. The third pattern observed was seen with *Sox 2* where hypomethylation first appeared at $1.0\,\text{BPA}\,\mu g/{kg}\,\text{BW}$ and gradually decreased further with increasing BPA doses, reaching a nadir at the highest BPA dose of $5,000\;\mu g/{kg}\,\text{BW}$ ($p < 0.01$).

![Dose--response analysis of promoter DNA methylation patterns of five previously identified $\text{E}_{2}$/BPA reprogramed rat prostate genes ([@c8]). *A*) Promoter methylation at each CpG site is expressed as $\text{mean} \pm \text{SEM}$ from four to five samples/group with $4–6\,\text{clones}/\text{sample}$ for each BPA dose, $\text{E}_{2}$ treatment and vehicle control. The exception is Creb3/4 of which bisulfite sequencing analysis was performed on pooled samples ($n = 5$) with six clones/sample. *B*) Mean % methylation of all promoter-region CpG sites combined across the separate doses. The dotted line represents the vehicle control total promoter % methylation for comparison.](EHP1050_f3){#f3}

Discussion {#s4}
==========

The present study fills several critical data gaps necessary to thoroughly assess the influence of developmental BPA, at levels relevant to daily human exposures, on prostate cancer risk with aging. Most notably, it provides a logarithmic dose--response analysis across separate rat prostate lobes, direct measurement of internal free BPA and BPA-G across doses in individual rat pups, documentation of PIN lesion progression to locally invasive carcinoma, and mechanistic connections to epigenetically reprogramed genes across multiple doses. At all doses tested, early-life BPA exposure alone was insufficient to drive prostate precancerous lesions with aging, which substantiates previous findings ([@c20]; [@c30]; [@c62]) and indicates that up to the current LOAEL ($5\;{mg/kgBW}$), BPA is not a complete carcinogen in the prostate. Nevertheless, we found that BPA exposures across multiple doses, prostatic lobes and endpoints act in conjunction with elevated estradiol levels, as seen with aging, to heighten prostate carcinogenesis and progression. Combined with previously published studies ([@c8]; [@c20]; [@c21]; [@c46]; [@c52]; [@c60]; [@c61]), the present work further supports the postulation that early-life BPA exposure acts on estrogen-sensitive prostate cells to epigenetically reprogram and prime selective genes for enhanced responses to later-life estrogenic triggers. To that extent, BPA may be considered an epigenetic initiator of tumorigenesis during early development that results in increased cancer risk to rising estrogens that act as a promoter ([@c49]).

Specific BPA dose--response patterns were observed across the separate prostatic regions, which aligns with known differential sensitivities to multiple hormones, including estrogens, in the prostate gland ([@c1]; [@c35]; [@c36]; [@c38]). Of particular note, the lateral prostate lobe exhibited maximal carcinogenic susceptibility to adult estradiol when neonatally exposed to $0.1\;\mu g\,\text{BPA}/{kg}\,\text{BW}$, that is, at a 100-fold lower dose than previously reported ([@c20]; [@c41]), despite no detectable free BPA or BPA-G 1 hr after exposure. This indicates that markedly lower BPA doses will be required to reach a LOAEL for the rat prostate. Remarkably, this low-dose BPA response was equivalent to that found with neonatal high-dose $\text{E}_{2}$. These results are similar to mammary gland lesions induced by perinatal exposure to the very low dose of 25 ng BPA/kg BW ([@c12]) and emphasize that BPA levels within the range of human gestational exposures can predispose to adverse effects with aging. That similar responses were observed with BPA and high-dose $\text{E}_{2}$ treatment, but not the low-dose $\text{E}_{2}$ treatment suggests that BPA may act through additional pathways beyond estrogen receptors as has been documented in many studies including our recent findings with human prostate progenitor cells ([@c10]; [@c21]).

Relative to the lateral prostate, the less estrogen-sensitive dorsal and ventral lobes and periurethral prostatic ducts exhibited a nonmonotonic dose response for $T + E$-induced PIN incidence and scores. That a rising carcinogenic response was observed across these three regions with rising neonatal BPA levels through the $100 - \mu g/\text{kgBW}$ dose, supports the biologic relevance of the response. Of note, a significant increase in PIN scores was found in periurethral ducts at $1\;\mu g\,\text{BPA}/{kg}\,\text{BW}$, when serum free BPA was $< \text{LLOQ}$, and rose to peak values at the $10\;\mu g$ dose when mean serum free BPA was $0.76\;{ng/mL}$, a value reported in some pregnant women ([@c16]). That peak neoplastic responses were observed between $10\,\text{and}\, 100\;\mu g$ BPA/kgBW and dropped to lower responses at the $5,000 - \mu g/{kg}$ dose in these three prostatic regions is likely explained by the multiple receptors and signaling pathways that can be engaged by different BPA levels, leading to a complex response pattern over the wide range of exposures tested herein ([@c9]; [@c58]). Similar shaped BPA dose responses have been reported for other organs and benign prostatic growth ([@c55]; [@c59]) and the current data extend this to carcinogenic susceptibility.

A complete prostate lobe-specific analysis was essential for multiple reasons: *a*) the rat dorsal and lateral lobes have homology in humans, both embryologically and histologically, whereas there is no human homolog for the ventral prostate ([@c34]), *b*) the individual lobes express specific genes, particularly the high-expression genes that encode lobe-specific secretory proteins ([@c15]), *c*) the ventral prostate is larger than the dorsal and lateral lobes combined and analysis of genes in entire prostatic complex will mask significant changes in the smaller lateral and dorsal lobes, and *d*) the ventral lobe undergoes branching morphogenesis between PND 1 and 6, whereas the lateral and dorsal lobes are delayed by 4--5 d, thus studies prior to 1 wk of age will be primarily ventral in nature ([@c18]). This may explain why a recent study that examined global genomic DNA methylation % and gene expression changes in the d-4 and -90 full prostate complex was not able to identify a dose--response effect in the prostate ([@c5]). This further emphasizes the necessity for lateral and dorsal prostate evaluations given that they are considered the human homolog in rodent studies and will have the greatest applicability to prostate diseases in aging men.

The pathological relevance of the PIN lesions to prostate cancer was confirmed in the present studies in two ways. First, significantly accelerated rates of epithelial proliferation and apoptosis were found in all prostate regions at the $10–100\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ doses when elevated and maximal PIN scores were noted, respectively. These aberrant cell turn-over rates are considered key evidence of similarity to human high-grade PIN, the precursor to prostate cancer ([@c48]). Second, and most importantly, the prostate PIN lesions progressed to microinvasion and adenocarcinoma in the lateral lobes of rats treated with neonatal BPA ($10\;\mu g/{kg}\,\text{BW}$) or $\text{E}_{2}$ plus adult $T + E$ when aged to 1 y as compared to neonatal vehicle-controls. Although not significant, similar trends were noted in the dorsal lobe and periurethral ducts aged to 1 y. That adult $T + E$ exposures alone had limited invasion (17%) and no glandular carcinoma in the lateral prostate, whereas the addition of neonatal BPA produced a 62% incidence of microinvasive carcinoma and 14% glandular carcinoma incidence clearly confirms, for the first time, that early-life BPA exposures heighten prostate cancer risk.

The route of BPA exposure in the present study deserves discussion. A prior study from our laboratory directly compared the BPA pharmacokinetics in PND 3 rat pups after exposure to $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ by s.c. injection or orally and further assessed prostatic lesions in adult $T + E$ treated rats on d 200 ([@c41]). Whereas free BPA was significantly higher at 30 min after s.c. injection compared with oral exposure, this rapidly declined by 1--2 hours to equivalent levels in the two exposure groups with serum values matching the present study. Importantly, the prostate exhibited nearly identical heightened susceptibility to PIN lesions with either exposure route suggesting that the early metabolic differences in free BPA did not influence the pathologic outcomes. A recent independent study comparing exposure routes in PND 3 rats reported equivalent serum free-BPA levels 1 hr postexposure in pups given $10\;\mu g\,\text{BPA}/{kg}\,\text{BW}$ by s.c. injection and oral administration of $50\;\mu g\,\text{BPA}/{kg}\,\text{BW}$, the current BPA NOAEL, with similar carcinogenic risk at both doses ([@c61]). Although the present experiments utilized the s.c. injection route to permit direct comparisons with previous datasets, we directly measured the internal BPA dosimetry in the neonatal pups, and most importantly, find significant prostatic lesions when free BPA was below detection limits. It is now appreciated that humans are exposed to BPA through multiple routes including ingestion, skin absorption, inhalation, and intravenous medical devices with which newborns are in increasing contact ([@c13]; [@c19]; [@c54]). As such, studies that utilize nonoral routes should not be discounted *a priori* and may in fact encompass the variety of human exposures to this chemical. Thus internal dosimetry measures utilizing a contamination-free system as performed herein should be the ultimate determinant of applicability of study results for risk assessment and relevance.

The measurement of free BPA and BPA-G in $25\;\mu L$ of sera permitted direct monitoring of BPA levels in individual exposed rats in this study, markedly increasing the robustness of the present results. Prior work on rat neonates required pooling sera from 10 pups for BPA quantitation ([@c41]; [@c61]), extrapolation from higher-dose exposures or utilization of isotopically labeled tracers ([@c11]). Further, until recently, direct BPA-G measures were not possible due to lack of an available standard, relying instead on enzymatic digestion for indirect BPA-G calculations ([@c11]; [@c41]). Using a direct assay, the current study found that the BPA-G levels were considerably higher than we previously observed in PND3 rats and result in a 2--15% level of free BPA that closely aligns with studies by Doerge for PND-4 rats ([@c11]). The higher levels of free BPA with increasing BPA doses is expected due to the immaturity of UDP glucuronosyltransferase 2 family, polypeptide B1 (Ugt2b1) expression and thus limited capacity for glucuronidation in the neonatal liver ([@c29]). As a result, the $100 - \mu g\,\text{BPA}/{kg}\,\text{BW}$ dose, which produced peak PIN lesions in the dorsal and ventral prostates, resulted in $20\;{ng/mL}$ free BPA 1 hr postexposure that, while far higher than daily exposures reported in the adult human population, has been reported in mid-gestational sera of pregnant women using a documented contamination-free sera collection and assay ([@c16]).

Complementing the nonmonotonic dose response in carcinogenic risk, we herein identified nonmonotonic dose responses for DNA hypomethylation in several gene promoters of d-200 dorsal prostates, with three of five examined genes (*Creb3L4, Tpd52, Pitx3*) showing marked changes only at the lowest BPA doses. This is supported by recent reports of nonmonotonic DNA methylation responses to low- and high-dose BPA in the mouse and human fetal liver ([@c14]; [@c26]). In addition to the nonmonotonic low-dose methylation marks, other patterns emerged including consistent *Paqr4* promoter hypomethylation at all doses and increasing Sox2 promoter hypomethylation with increasing BPA levels. The five prostate genes examined at d 200 in the present study were selected from a previous genome-wide DNA methylation analysis of the same rat cohort that identified 86 genes differentially methylated by neonatal BPA exposure in d-90 dorsal prostates as compared to neonatal vehicle controls ([@c8]). These genes were specifically chosen as potential BPA- reprogramed gene candidates because they exhibited an inverse relationship between DNA methylation and gene expression at d 90, long after neonatal BPA exposure. That differential methylation modifications persist through d 200 indicates that these genes are permanently reprogramed throughout life by developmental BPA exposures. Our previous work found that upon neonatal low-dose BPA treatment, the prostatic *de novo* DNA methylation transferases (Dmnt3a/b) and methyl-CpG binding domain proteins (Mbd2/4) were elevated throughout life and modified by adult estrogens which may underpin the dynamic alterations in DNA methylation marks across genes, doses and with aging ([@c52]). It is important to note that the hypomethylation marks in the present study were quantified in the d-200 dorsal prostate in the absence of adult hormone treatment. Given that the onset of dorsal lobe PIN lesions and microinvasion was only observed with the addition of adult $T + E$, the present data suggest that the altered gene methylomes may contribute to increased carcinogenic susceptibility to adult estrogen exposure. Utilizing the same rat prostate model, a parallel mechanism of neonatal BPA- reprogramed genes in the KEGG prostate cancer pathway was recently identified ([@c60]). In those studies, persistent H3K4me3 marks were elevated at several cancer-associated gene promoters, a function of increased histone methyltransferase mixed-lineage leukemia 1 (MLL1) activation by BPA, which primed them for enhanced sensitivity to $T + E$ induction in the adult prostate. Undoubtedly several epigenomic modifications initiated by early-life BPA, including altered noncoding RNAs such as SNORDs as recently shown in prostate progenitor cells ([@c8]; [@c14]), act in parallel to poise the prostate gland for increased carcinogenic risk as a function of later-life events, supporting the proposal that BPA acts as an epigenetic initiator in early life as epigenetic marks are established in developing tissues.

Given that the five BPA- reprogramed genes examined herein were hypomethylated with aging, their expression may be aberrantly elevated in the aging prostate. *Paqr4* (progestin and adipoQ receptor family member 4) was hypomethylated at equivalent levels by all BPA doses and matched high-dose $\text{E}_{2}$, suggesting maximal and sustained expression changes at low-to-high BPA exposures. Although studies on *Paqr4* are limited, AdipoQ, its ligand, plays an important role in cellular metabolism and abnormal expression has been associated with prostate cancer risk ([@c25]). *Pitx3* is a homeobox transcription factor with established roles in development and stem cells, although its function in the prostate has not been examined. Interestingly, although *Tpd52* and *Creb3L4* were hypermethylated in d-90 prostates by neonatal BPA/$\text{E}_{2}$ exposures with resultant down regulation of gene expression ([@c8]), the profiles of these two genes was reversed with aging, becoming significantly hypomethylated by d 200. This is noteworthy because Tpd52 and *Creb3L4*, along with *Sox 2*, are upregulated in prostate cancer ([@c24]; [@c27]; [@c53]) and, along with *Pitx3*, have established roles in stem cells. Because epigenetic mechanisms are central to maintaining stem cell identity, disruption of their epigenome may give rise to high-risk progenitor populations that readily become neoplastic upon gain of additional insults throughout life ([@c49]). Taken together with our recent findings that BPA targets human embryonic and adult prostate stem cells and modifies their epigenome ([@c4]; [@c21]; [@c42]; [@c43]) and that chronic low-dose BPA treatment alters rat prostate stem cell homeostasis ([@c23]), a picture emerges whereby early-life BPA exposure heightens later-life carcinogenic risk by permanently modifying prostate stem and progenitor cells for increased sensitivity to carcinogenic hits. Although stem and progenitor cells were not studied in the present experiments, the epigenetic modifications of certain prostate genes related to stemness found herein leads us to postulate that BPA exposures might epigenetically poise prostate epithelium towards a cancer stem cell phenotype following additional hormonal stimuli. Of particular note, these genes were found to be associated with recurrence-free survival in human prostate cancer when the Cancer Genome Atlas (TCGA) data set was interrogated, indicating potential clinical relevance of these genes to human prostate cancer ([@c8]).

In summary, the present study extends our knowledge on the effects of developmental BPA on adult prostate health, documenting a dose-dependent effect, providing internal BPA dosimetry for direct comparisons to humans and showing that low-dose exposures heighten the risk for developing lesions that progress to prostate cancer. That PIN progresses to adenocarcinoma provides the required biologic and pathologic relevance of these earlier lesions and raises the bar for adverse outcomes due to early-life BPA exposures. Further, dose-specific modifications in the DNA methylome of genes connected to human prostate cancer provide a mechanistic framework for connecting early-life exposures to later-life disease risk. Together, this data reinforces the assertion that low-dose BPA at levels comparable to human exposures negatively affects prostatic health. This may bear particular relevance to at-risk populations for developing prostate cancer due to race, metabolic polymorphisms, hormonal therapeutics and/or genetics.
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